Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of MP03-36 (Azelastine 0.15%) in Seasonal Allergic Rhinitis
NCT00660829Phase 3Completed
- Sponsor
- Meda
- Start
- Dec 2007
- Primary completion
- Feb 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in seasonal allergic rhinitis (SAR) comparing Placebo with 0.15% Azelastine Hydrochloride (2 arms). Primary endpoint: Total Nasal Symptom Score at 14 days. Started Dec 2007; status: completed.
02
Drugs
azelastine
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on NCT00660829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00660829.